Authors: Gilligan, PJ Baldauf, C Cocuzza, A Chidester, D Zaczek, R Fitzgerald, LW McElroy, J Smith, MA Shen, HSL Saye, JA Christ, D Trainor, G Robertson, DW Hartig, P

Citation: Pj. Gilligan et al., The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-alpha]-pyrimidine: A corticotropin-releasing factor (hCRF(1)) antagonist, BIO MED CH, 8(1), 2000, pp. 181-189

Authors: He, LQ Gilligan, PJ Zaczek, R Fitzgerald, LW McElroy, J Shen, HSL Saye, JA Kalin, NH Shelton, S Christ, D Trainor, G Hartig, P

Citation: Lq. He et al., 4-(1,3-dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine: A portent, orally bioavailable CRF1 receptor antagonist, J MED CHEM, 43(3), 2000, pp. 449-456

Authors: Corbett, JW Ko, SS Rodgers, JD Jeffrey, S Bacheler, LT Klabe, RM Diamond, S Lai, CM Rabel, SR Saye, JA Adams, SP Trainor, GL Anderson, PS Erickson-Viitanen, SK

Citation: Jw. Corbett et al., Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1, ANTIM AG CH, 43(12), 1999, pp. 2893-2897